Tusk Therapeutics Ltd

Tusk Therapeutics Ltd is a UK-based biotechnology company focused on developing innovative therapies aimed at treating challenging diseases through advanced immunotherapy solutions. Tusk Therapeutics Ltd specializes in the research and development of novel immunotherapies. Founded in 2015 and headquartered in the UK, the company has completed 2 significant deals, with its most recent transaction being a TRADE SALE in September 2018 for EUR 70. 00 mn, bringing the total amount raised to EUR 70.

00 mn. No information on the founders or previous companies was provided. Tusk Therapeutics Ltd develops immunotherapeutic products designed to address significant medical needs. The company’s portfolio includes therapies targeting cancer and other serious conditions, aimed at modulating the immune system to improve patient outcomes.

Their client base includes healthcare providers and research institutions, ensuring that innovative treatment options are accessible to those in need. In 2016, Tusk Therapeutics Ltd reported zero revenue. The company's EBITDA for the same year was also zero, indicating it had not generated profit during that period. Tusk Therapeutics Ltd plans to utilize its recent funding from the TRADE SALE to advance its pipeline of immunotherapeutic products.

The company aims to launch new therapies targeting various diseases, although specific release dates have not been disclosed. Additionally, Tusk Therapeutics is exploring opportunities to expand into new geographic regions, with a focus on increasing its market presence in Europe and North America in the coming years.